Background. There is a wide disparity in the use of automated peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD) in the UK. This may be due to a perceived quality of life and technique survival advantage with APD, although evidence is lacking. Methods. We conducted a single-centre retrospective study of incident end-stage renal disease initiating APD and CAPD with data collected prospectively over 5 years. PD modality was based on patient preference. Health status was assessed using SF-36 questionnaires at initial and 1-year follow-up appointments. Results. Three hundred and seventy-two patients were included: 194 patients chose APD, and 178 patients chose CAPD. CAPD patients were generally older and more dependent than APD patients. Univariate analysis for technique survival was inferior for CAPD (relative risk for failure 1.46, 95% CI 1.08-1.97). But on multivariate analysis when comorbidity was added into the model, PD modality was no longer a significant predictor of technique survival. There was no difference in decline in residual renal function. Baseline CAPD patients had worse health status (HS); mean (SEM) physical and social composite scores were 32.3 (0.9) vs 36.5 (0.9) and 33.3 (1.2) vs 40.3 (1.2). After 1 year, HS scores for CAPD and APD patients were similar, but the improvement in HS scores correlated with baseline scores (PD modality was not an independent predictor of the change in HS). Conclusions. This study did not show any advantages of APD over CAPD in terms of technique survival or HS. There is no evidence to support physician bias towards one PD modality, and both should be available to allow patient choice.
Introduction
In the UK, there is a wide diversity in the use of peritoneal dialysis (PD) to treat incident patients with end-stage renal failure. Moreover, there are also wide variations between the proportions of patients undergoing automated peritoneal dialysis (APD) compared with continuous ambulatory peritoneal dialysis (CAPD) (Figure 1 ). Such wide variation within a country is likely to be related to physician bias rather than geographic variations in patient preference. However, the evidence to support evidence-based bias towards one modality is weak. The studies that have randomized patients to either APD or CAPD were reviewed in a meta-analysis and showed no differences in survival [1] . However, only three small studies could be included and were underpowered. The two large multicentre databases (NECOSAD [2] and USRDS [3] ) that showed no differences in patient and PD technique survival were contradicted by other observational studies [4, 5] .
Even if there are no differences in survival, many physicians believe that there are other clinically relevant differences between the two modalities. In particular, many believe that APD is less onerous for patients, and this might translate into better quality of life for patients and their carers. It has also been suggested that peritonitis rates may be better for patients on APD vs CAPD, although APD was associated with a more rapid decline in residual renal function in one study [6] .
At our hospital, both APD and CAPD are widely utilized, and the decision on initial PD modality is based entirely on patient preferences. We undertook a study to examine the outcomes of our incident PD patients (CAPD or APD) to determine technique survival and other outcome parameters including changes in health status (often referred to as quality of life) in an intention-totreat analysis.
Materials and methods
The study was performed in accordance with the Ethical Committee guidelines set out by the East London and The City Health Authority. Prior to having their PD catheters inserted, patients were assessed by the Pre-Dialysis team that has been led by the same individual since 2002. The patients' preference for APD or CAPD was recorded. We have performed an intention-to-treat analysis examining the effect their choice of modality had on subsequent clinical outcomes.
Clinical data and laboratory investigations
A review of all incident patients starting peritoneal dialysis between 1 January 2003 to 1 January 2008 at our centre was performed. The study was therefore retrospective in design, although all the data extracted for analysis was entered contemporaneously. Clinical data including comorbidity data submitted to the Renal Registry, United Kingdom were collated from detailed computerized records and review of patient, medical and nursing notes. We recorded any dialysis modality changes but deaths within 30 days of switching on to hemodialysis were considered to be death on PD.
Comorbid conditions collected included history of angina, previous myocardial infarction, cerebrovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, malignancy (excluding basal cell carcinoma), current claudication, smoking (current or history of smoking within the previous year), history of non-coronary angioplasty/stenting/vascular grafts and history of heart failure. Patients were also asked during their clinic appointments if they performed the dialysis independently of their partner or if their carer was required to help with the dialysis on a daily basis. This dataset was therefore a self-reported assessment and the option given to the patient to choose were For analysis, we grouped the final three options and classified these patients as "dependant on carer". These methods of assessing comorbidity and dependency have been used in other clinical studies [7, 8] .
Residual renal function (RRF, defined by urine volume and the mean of urea and creatinine clearance normalized to BSA) was assessed approximately 3 months after initiation of PD and as close to the anniversary of starting PD as possible (timed to coincide with routine clinic appointments, but delayed if within 30 days of peritonitis or other serious reversible intercurrent illness).
Episodes of peritonitis were also recorded for each patient with the diagnosis of peritonitis being based on at least two of the following criteria: abdominal pain or cloudy peritoneal dialysis effluent, leucocytosis in peritoneal fluid effluent (white blood cell count at least 100/mm 3 ), or positive Gram stain or culture from effluent.
Health Status assessments
Patients starting PD at Barts and The London Hospital NHS Trust between June 2003 -June 2006 had their HS assessed by the Medical Outcomes Study 36-Item Short Form survey (SF-36) questionnaires. These were given to patients attending the pre-PD training course or during their initial PD clinic. They were subsequently given to patients to complete when they attended their routine PD clinic appointments approximately 1-year later. The patients were encouraged to complete and return the questionnaires on that day although a small minority chose to post the questionnaires back to the PD unit or returned them at their next visit. To minimize the risk of coercion, no reminders were sent to patients. The questionnaire was only available in English. The SF-36 scores for eight domains: physical functioning (PF), physical role (PR), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), emotional role (EM) and mental health (MH). In addition, summary scores are calculated for physical (PCS) and mental (MCS) components. The results were expressed with the norm-based scoring such that a general US population would score a mean of 50 (SD 10) for each domain.
Statistics
Continuous variables are expressed as mean with SEM. Categorical variables are expressed as percentages or proportions. For the survival analysis, the study population was divided into two groups based on the intention-to-treat PD modality. Kaplan-Meier PD technique survival curves (censored for transplantation, recovery of renal function and transfer to another PD unit) were calculated and the log-rank test was computed to compare curves. Cox regression analyses were also performed adjusting for various co-founders that included age, Karnofsky score, diabetic mellitus status, gender, ethnicity and dependency on others to perform PD. The changes in residual renal function during the follow-up period in the two groups were calculated for each individual patient. These were compared using Student t-test. For the health status analysis, we compared the normalized composite scores and changes in composite scores using Cox regression analyses to assess correlation between variables of interest a P of 0.05 was considered the level of significance. Analyses were performed with SPSS version 16.0 (SPSS Inc, Chicago, Ill).
Results

Patient demographics
The demographics of the incident PD patients during the study period are shown in Table 1 . There were 194 patients that elected during their pre-dialysis education to undergo primary APD whilst 178 patients chose CAPD as their first PD modality. The patients that elected to have CAPD were older than those that chose APD (57.6 yrs vs 51.3) and had poorer Karnofsky Performance Status Score. Patients that selected CAPD were equally dependent on the spouse or relatives to help perform the dialysis exchanges. However, there were no significant statistical differences for sex, proportion of patients with diabetes mellitus, ethnicity and comorbidity (assessed by the UK Renal Registry score).
PD Technique survival
The mean (SEM) PD follow-up period for APD and CAPD patients were 2.20 (0.10) and 2.18 (0.11) years respectively. During this time, 12 APD and 15 CAPD patients died, 63 APD and 83 CAPD patients transferred to HD and 51 APD and 31 CAPD patients were transplanted. Figure 2 shows the Kaplan-Meier technique survival curves based on whether the patients elected to start on APD or CAPD. In Figure 2a , the technique survival was censored for patients that recovered renal function (n = 6), was transferred out of the unit (geographic relocation, n = 6) or were transplanted (n = 82). Technique survival was statistically better for the patients that started on APD. However, it might be argued that patients who died whilst performing PD are not a reflection of PD technique failure given the advanced age and high comorbid burden of the patients. Hence the analysis has been repeated in Figure 2b , this time censoring also for death. Re-analysis still showed statistically superior technique survival of patients starting on APD. The relative risk of technique failure of patients starting on CAPD was 1.46 (95% CI between 1.08 and 1.97) without censoring for death and was 1.47 (95% CI between 1.06 and 2.04) when the data was censored for deaths.
However, when we included age, Karnofsky score, diabetic mellitus status, gender, ethnicity and dependency on others to perform PD, then the initial PD modality was not an 'independent' predictor of technique outcome. Only Karnofsky score and dependency on others to perform PD were statistically significant predictors of PD technique survival (Table 2) .
Residual renal function
We identified 277 patients (147 APD, 130 CAPD) that had serial assessments of their residual renal function. However, we censored 16 APD and 19 CAPD patients that were effectively anuric (24-h urine output of less than 200 mL) at the initial assessment. The mean period between the follow-up assessments was 9.5 (0.3) months. There was no statistically different change in the decline in CrCl between the APD or CAPD patients (equivalent to 15.7 L/wk/yr vs 15.4 L/wk/yr respectively, P = ns). There were also no statistical differences in the rate of decline in other parameters of residual renal function assessed by measurements of renal kt/v and 24-h urine volume (Table 3) . 
Peritonitis Rates
The total duration of PD of all study patients at the time of last follow-up was 10 075 patient-months (5323 for APD patient-months and 4752 for CAPD patient-months).
There were a total of 310 episodes of peritonitis (145 episodes in the APD patients and 165 in the CAPD patients. This meant that overall peritonitis rate was 1:32.5 patientmonths. For patients treated with APD, peritonitis rate was 1:36.7 and for CAPD this was 1:28.8 patient months representing an odds ration of 0.78 (95% CI 0.63 -0.98) in favour of APD. However, when analysed by Kaplan Meier 'peritonitisfree survival', although there was a trend in favour of APD, this did not reach statistical significance (P = 0.13), Figure 3 . We also performed a sub-set analysis of patients that remained on PD for at least 18 months (i.e. avoid the confounding effect of patients dropping out of PD for nonperitonitis related factors). Of the 137 APD patients, 38 (28%) suffered an episode of peritonitis within 18 months. Of the 112 CAPD patients, 35 (31%) suffered an episode of peritonitis within the same time period (P = ns by Chi Square).
Health Status/Quality of Life
We collected completed baseline SF-36 questionnaires from 224 patients (119 APD and 105 CAPD). The scores for all aspects of quality of life were significantly below that expected for a normal population. The patients that chose to have CAPD had significantly lower baseline HS scores for all domains ( Figure 4) ; the mean (SEM) physical composite score and mental composite score for CAPD patients were 32.2 (0.9) and 33.3 (1.2) compared with the APD patients who scored themselves, 36.5 (0.9) and 40.3 (1.2) respectively (P < 0.001 for both). These scores are normalized to a US population with a mean score of 50 and an SD of 10. Thus, 95% of normal people have scores between 30.4 and 69.6. All composite (PCS and MCS) scores for our patients are within this range although in the case of CAPD, near the lower end suggesting that at the time our patients started CAPD, they have severely compromised quality of life.
On multivariate linear regression analysis using the factors APD vs CAPD, age, sex, ethnicity (white vs nonwhite), diabetes mellitus, dependency score (for PD) and Karnofsky score, we found that choice of APD vs CAPD, age and Karnofsky score were significantly associated with better baseline PCS and MCS (Table 4 ). The factors we used in our model accounted for only 14% of the variability of the PCS scores and 11% of the MCS scores. CrCl = mean of the creatinine and urea clearance normalized to body surface area). After approximately 12 months of follow-up, the HS scores for 42 APD patients were similar to 29 CAPD patients. The follow-up PCS scores were 39.8 (1.7) vs 36.0 (2.0) (APD vs CAPD) and the MCS scores were 45.5 (1.6) vs 37.1 (2.2) (APD vs CAPD), all P = ns. We confirmed that APD vs CAPD was not statistically associated with follow-up HS scores on multivariate linear regression analysis using the same factors listed above. However, baseline HS scores did correlate with follow-up HS scores (P < 0.005 for PCS and MCS). Thus, although the CAPD patients generally had better improvement in MCS and PCS scores over time, on multivariate analysis, this was statistically related to their lower baseline scores (i.e. all patients tended to improve with dialysis, but because CAPD patients started at a lower level, their improvement was greater).
Discussion
The usage of APD appears to be increasing at the expense of CAPD; in the UK, 22% of centres have reported that > 90% of PD patients were on APD in 2007. What might be the reasons that is driving the increasing use of APD; is it purely driven by patient preference or is it influenced by physician beliefs that APD is superior to CAPD [3] ? The Cochrane review published in 2007 suggested that APD may result in a lower peritonitis rates. However, only two studies (107 patients) were included in this analysis [1] . In the Cochrane review, mortality was not different but two retrospective observational studies from Mexico and USA suggested that PD survival technique was superior for APD [4, 5] but comorbidity was not collected in these studies. We wished to determine if we could corroborate these findings. Although we confirmed that patients starting APD appeared to have a superior survival, on multivariate analysis that includes detailed comorbidity scoring, PD modality was not an independent factor that influenced patient or PD technique survival. We believe that comorbidity is such an important cofounder that any study comparing survival that does not include this parameter may not be valid and this led to the wrong conclusion by Ramos-Sanchez et al. (Mexican study) and Guo and Mujais (US using Baxter Healthcare database) that APD is superior to CAPD. In our analysis, we used the Renal Registry comorbidity score that was collected contemporaneously and prospectively. However, it must be acknowledged that this score has not been validated as a survival index. An alternative strategy would have been for us to rescore each patient using an externally validated score Charleston or Davies scores but this would have potentially introduced bias. In our defence, we also included Karnofsky score in our analysis. Although this is an assessment of function, not comorbidity, it provided a prospectively collected indicator of 'disease burden'. It is reassuring that recent analysis of US RDS also showed no differences in survival [9] .
In our analysis of PD technique survival, we considered switching from CAPD to APD and vice versa to be successful PD. However, it should be noted that the proportion of CAPD patients that switched to APD was higher than the proportion of patients that switched from APD to CAPD (at 18 months 21 vs 13% had switched). APD patients switched to CAPD early (within 3 months and usually because of PD catheter drainage issues) whereas patients that switched from CAPD to APD did so throughout the first 12 months of starting PD (suggesting that as patients became more confident about the PD technique, they wished to convert to a modality that increased their independence).
The Cochrane review and the study of PD patients in Mexico suggested that use of APD was associated with a lower rate of peritonitis. Our study also suggests that APD may be associated with lower peritonitis rates (1:36.7 vs 1:28.8), but, when we examined peritonitis-free survival rates, we found no statistical difference. We believe that peritonitis-free survival analysis avoids high-risk patients that may be over-represented in the CAPD cohort, contributing a disproportionate number of peritonitis episodes. In other words, statistical analysis comparing peritonitis rates is flawed because the risk of repeated episodes is not an independent factor. Equally, lack of difference with the peritonitis-free survival analysis might be due to a type II statistical error. However, the number of patients in our study population was 372, and if APD conferred an advantage that can only be detected through a much larger study, the odds ratio would be so close to 1 that one has to question its clinical relevance given that technique success Table 4 . Multivariate linear regression analysis of factors that might be associated with patients' health status/quality of life scores. Coefficient and probability (P-factor) of each factor in the model correlating with HS is shown has to be judged on wider criteria that must include quality of life. In this respect, our study is of particular interest because we have baseline and follow-up SF-36 scores for a significant cohort.
There are few studies examining the impact of different PD modalities on patients' health status/quality of life. The study by De Wit et al. [10] included prevalent PD patients matched for dialysis vintage. They showed that physical function scores were impaired compared with the general population. Interestingly, both APD and CAPD patients had mental health scores within the normal limits of the general population, but the scores for APD were higher than CAPD patients. However, these differences may have existed prior to dialysis initiation and may not be related to dialysis modality per se. A similar criticism can be levelled at the much larger study by Diaz-Buxo et al. [11] who also showed that prevalent APD patients had better mental health scores than CAPD and HD patients. Interpreting cross-sectional data on prevalent patients is difficult as marked differences in baseline HS may exist (as seen in the NECOSAD study [12] ).
Our study has shown that patients that select APD were generally younger, had less comorbidity less comorbidity and were more independent that patients choosing CAPD. For this reason, it is perhaps not unexpected that baseline HS scores for APD are superior to CAPD. We also found that the improvement in HS scores over a 1-year follow-up appeared greater for CAPD patients than APD patients but multivariate analysis suggests that baseline HS scores rather than choice of PD modality correlated with the improvement in HS; i.e. people with low HS scores at baseline improved more than patients who already had a reasonable HS, and the improvement was independent of whether patients were on APD or CAPD.
SF-36 is a well-validated method of assessing HS. However it is self-reported and therefore it is important to relate the scores of patients in our study with the results of other related studies. The NECOSAD study, which was previously discussed, showed that at the time of starting dialysis, normalized MCS and PCS ranged between 37 and 42 whilst our scores were similar (32-40).
It should be noted that only a small proportion of patients that had initial HS assessment repeated their assessment after 1 year. This is partly due to the high turnover of PD patients; only 28% of PD patients at our unit was still on PD after a mean of 2 years of follow-up. Higher numbers of APD patients were transplanted and therefore there may be a selection bias that the "fittest" APD patients would be transplanted whilst the "most ill" CAPD patient died resulting in the apparent greater increment in HS of CAPD patients. However, validation of our SF-36 data also comes from the fact that we were able to confirm what might be intuitive, that age and clinicial scores of physical function (Karnofsky) correlated with self reported baseline HS. Age as an independent predictor of HS was also confirmed by Baiardi et al. but they did not perform more detailed assessment of comorbidity beyond the presence of diabetes mellitus [13] . Another study suggest that ethnicity and gender might influence self-reported HS [14] . We were unable to find any effect of ethnicity or gender on HS at baseline and after 12 months of PD.
Although there have been suggestions that the intermittent nature of APD might result in greater decline in residual renal function [6] , we were not able to confirm this. However, our conclusion has to be tempered by the possibility of informative censoring. To avoid dropouts confounding the interpretation of "final" RRF, we analysed the changes in RRF for each patient that had a follow-up 24-h urine collection. This means that many patients who did not remain on PD for 1 year were excluded from the analysis. It is possible that if a dialysis modality caused a rapid decline of RRF, then early dropout from that group would mean that analysis would be biased. Although possible, our previous analysis on PD technique survival makes this unlikely.
We accept that a major drawback to our study is the retrospective observational design. Nevertheless, studies like ours can be useful and provocative [15] . The strength of our single-centre study is that it is relatively large and we collected complete comorbidity data. Our study suggests that physicians should be reassured that both APD and CAPD are effective and there is no evidence to suggest that mortality, PD technique survival, peritonitis rate or residual renal function will be different. The choice of modality should therefore be patient-centred. Whilst patients with greater comorbidity and lower HS tend to select CAPD as their initial modality, their HS improves most after dialysis initiation. Of course, we cannot exclude the possibility that their improvement might have been even greater if the patients chose APD, but we think it is unrealistic as it would mean that the HS of these CAPD patients would have overtaken the HS score of younger and fitter patients who started directly on APD. Thus, both PD modalities should continue to be offered by PD units and their care individualized according to their needs and concerns.
